Champions Oncology (CSBR) Enterprise Value (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Enterprise Value of $129000.0 for Q2 2026, up 101.32% year-over-year from $64077.6 in Q2 2025, and up 101.83% quarter-over-quarter from -$7.0 million in Q1 2026.
Champions Oncology (CSBR) Enterprise Value (2010 - 2026) Analysis & Trends
Champions Oncology's Enterprise Value history runs 17 years deep, the most recent figure standing at $129000.0 for Q2 2026.
- In Q2 2026, Enterprise Value rose 101.32% year-over-year to $129000.0; the TTM figure through Apr 2026 stood at $129000.0 (up 101.32% YoY), while the FY2026 annual figure was $129000.0, up 101.32% from the prior year.
- Enterprise Value for Q2 2026 stood at $129000.0, up from -$7.0 million in the prior quarter.
- The five-year high for Enterprise Value was $129000.0 in Q2 2026, with the low at -$11.6 million in Q1 2023.
- The 5-year median for Enterprise Value is -$7.6 million (2022), against an average of -$6.7 million.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value slumped 273.76% in 2025, then soared 101.32% in 2026.
- Champions Oncology's Enterprise Value stood at -$10.8 million in 2022, then soared by 49.08% to -$5.5 million in 2023, then soared by 50.05% to -$2.8 million in 2024, then plunged by 207.01% to -$8.5 million in 2025, then soared by 101.53% to $129000.0 in 2026.
- Business Quant data shows CSBR's Enterprise Value at $129000.0 in Q2 2026, -$7.0 million in Q1 2026, and -$8.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 129,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 129,000.00 |
| Jan 31, 2026 | -7.03 Mn |
| Oct 31, 2025 | -8.46 Mn |
| Jul 31, 2025 | -10.30 Mn |
| Apr 30, 2025 | -9.79 Mn |
| Jan 31, 2025 | -3.20 Mn |
| Oct 31, 2024 | -2.75 Mn |
| Jul 31, 2024 | -2.89 Mn |
| Apr 30, 2024 | -2.62 Mn |
| Jan 31, 2024 | -4.50 Mn |
| Oct 31, 2023 | -5.51 Mn |
| Jul 31, 2023 | -4.90 Mn |
| Apr 30, 2023 | -10.12 Mn |
| Jan 31, 2023 | -11.65 Mn |
| Oct 31, 2022 | -10.83 Mn |
| Jul 31, 2022 | -8.10 Mn |
| Apr 30, 2022 | -9.01 Mn |
| Jan 31, 2022 | -8.70 Mn |
| Oct 31, 2021 | -4.80 Mn |
| Jul 31, 2021 | -4.00 Mn |